A novel NSC small molecule inhibitor inhibits proliferation of triple-negative breast cancer cells through metabolic reprograming.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology(2022)
Abstract
Altogether, our data indicate that NSC small molecule inhibitor may exhibit anti-tumor activity in TNBC cells and provide a rationale for further investigation of the potential of NSC small molecule inhibitor as an attractive therapeutic drug for TNBC. Further in-depth investigations are required to evaluate the exact targets and mechanism of this potent small molecule inhibitor, and its anti-neoplasm effects on TNBC in vivo.
MoreTranslated text
Key words
small molecule inhibitor,triple‐negative breast cancer,cancer cells,breast cancer
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined